Breakthrough Technology Banner

Seraph 100 as Seen on 60 Minutes

Military Programs Aiming to End Pandemics Forever

ExThera Medical Launches ONCOBind™ Extracorporeal Procedure Program to Treat Metastatic Cancer

Investigational Device Exemption (IDE) Approval news and learn more about this exciting program for the treatment of metastatic cancer patients

COVID-19 Pandemic Heroes: Dr. Stephen A. Chitty IV

Physician Hero Award, Southeast Georgia Health System, Georgia Hospital Association

A story about 2 physicians, a dedicated clinical team, and a new treatment during an extraordinary time. In memory of Dr. Thomas Hodge.

Seraph 100

Pathogen Absorption Therapy

ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter is a groundbreaking hemoperfusion technology that addresses unmet clinical needs for treating severe COVID-19.

Pathogen Adsorption Mechanism of Action

Debulking Pathogens from the Bloodstream

ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter surface technology overview.

Publications About the Seraph 100

Learn what clinical study observations are being revealed in peer-reviewed literature

Groundbreaking

COVID-19 Pathogen Adsorption Therapy

ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter is a groundbreaking hemoperfusion technology that addresses unmet clinical needs for treating severe COVID-19.

An Exciting Option for Critical Care Teams

The Seraph 100 uses microbead adsorption media with chemically-bonded heparin to mimic the binding sites that COVID-19 uses when they invade the bloodstream. COVID-19 is removed from the bloodstream, and once bound, remains in the filter.

Seraph 100 Mechanism of Action: How it works

Patients Tell Their Stories

Extracorporeal—meaning outside the body—blood purification treatments are usually reserved for the severely or critically ill patient. Learn more about how Seraph 100 is used to treat COVID-19.

MM0001 Rev B